Objective To investigate the expression and prognostic value of vascular endothelial growth factor receptor 3(VEGFR-3) in human breast cancer. Methods A tissue microarray containing cores was constructed from 173 female patients with primary breast cancers(experimental group) and 19 female patients with benign breast lesions(control group) between March 2004 and June 2007. HE staining was performed to determine the quality of tissue microarray and immunohistochemistry staining was used to detect VEGFR-3 expression in the tissue microarray. Statistical analysis was performed to show the association between VEGFR-3 expression and clinicopathologic parameters. Results Histological examination showed that the tissue microarray had good quality, which could represent the histological characteristics of breast cancer and benign breast lesions. VEGFR-3 was expressed in 55.5%(96/173) breast cancer patients of experimental group, while the expression was negative in lesions of control group. VEGFR-3 expression rate had no signii cant relation with age, estrogen receptor, and progesterone receptor(P 0.05). VEGFR-3 expression rate correlated positively with tumor size and pathological staging compared to VEGFR-3 negative tumors(P 0.05). The positive expression rate of VEGFR-3 in breast cancer with lymph node metastasis was signii cantly higher than that without lymph node metastasis(P 0.05). Furthermore, VEGFR-3 positive staining correlated with human EGF receptor 2 expression(P 0.05). Conclusion The expressions of VEGFR-3 in human breast cancer have close relations with lymph node metastasis. Thus, VEGFR-3 may be a potential prognostic indicator and a new anti-cancer target for breast cancer.
Objective To explore the upper digestive tract and its countermeasures of complications after stenting. Methods 43 patients with upper gastrointestinal tract malignant were treated with metal stent stenosis. The therapeutic effect and complications were observed. Results All 43 cases were successful,and the success rate was 100%. The major postoperative complications were: pain and foreign body sensation,gastroesophageal reflux,bleeding,stent migration and the stenosis. 1 cases after 3 months was dead of bleeding,and the other complications were improved by symptomatic treatment. Conclusion For patients who are unable or unwilling to operation of malignant obstruction of upper digestive tract,metal stent implantation in the treatment of obstructive symptoms is safe and effective.
Objective:To investigate the relationship between polymorphism of thymidylates synthease gene in the 5’-untranslated region(5’-UTR) and 3’-untranslated region(3’-UTR) and therapeutic effect of stomach cancer (SC)to fluorouracil-based chemotherapy. TS gene promoter have either doubler or triple tandem repeats of a 28bp sequence in 5’-UTR and a 6bp variation at bp1494 in 3’-UTR. Methods:Seventy-four advanced SC patients were analyzed, which were diagnosed by pathology. All patients were treated with 5-FU-based chemotherapy and DNA of peripheral blood leukocytes was obtained before chemotherapy. TS 5’-UTR and 3’-UTR genotypes were detected by PCR-DHPLC method. Results:Of all the 74 cases,the proportion of 3R/3R genotype and 2R/2R, 2R/3R genotypes were 21.6%(16/74) and 78.4%(58/74). The response rates to chemotherapy were 6.3%(1/16) and 36.2%(21/58). The latter was significantly higher than the former, (χ2=4.05, P0.05). Of all the 74 cases, the proportion of TS 5’-UTR +/+6bp,+/-6bp and-/-6bp were 5.4%(4/74),52.7%(39/74)and 41.9%(31/74). The response rates to chemotherapy were 0(0/4),25.6%(10/39)and 41.9%(13/31). There was no significant difference in these groups(P=0.076). Conclusion:The study suggested that the polymorphism of TS 5’-UTR was associated with therapeutic effect of SC to 5-FU. However,there was no relationship between the polymorphism of TS 3’-UTR and the therapeutic effect of 5-FU. It was suggested that detection of TS 5’-UTR genotype could guide the chemotherapy of the advanced SC.
Objective To compare immunohistochemical(IHC) profiles(ER, PR, Her2) of breast cancer before and after neoadjuvant chemotherapy and to assess the subsequent effects on hormone receptor status. Methods Expressions of ER,PR,Her2 of 54 patients with breast cancer were measured before and after neoadjuvant chemotherapy.Results Of the 54 carcinomas, there were 48.1% positivity for ER pre-neoadjuvant therapy and 44.4% positivity forpost-treatment(P=0.7), 40.1% positivity for PR pre-neoadjuvant therapy and 22.2% positivity for post-treatment(P=0.038), and 63% positivity for HER2 IHC pre-treatment and 61% positivity for post-treatment(P=0.843). Conclusion Neoadjuvant chemotherapy has no effect on the profiles for ER, Her2 IHC in primary breast carcinomas, and further investigation is warranted to assess reproducibility of technique and investigate clinical implications of significant loss of PR status.
